Alzheimers Drug Discovery Foundation

Analysis

Alzheimers Drug Discovery Foundation is a registered charity in United States, based in New York, NY. It received its IRS tax-exemption ruling in September 2005, 21 years ago. Its declared purposes cover social science, which this site groups under arts, culture, heritage and science. The IRS classifies it as a publicly supported organisation (donations from the general public) under section 501(c)(3), and contributions to it are listed as tax-deductible.

In the financial year ending December 2023, Alzheimers Drug Discovery Foundation reported income of $37.7m and spending of $61.9m, spending 164% of what it took in. Across the 5 years on record, from December 2019 to December 2023, income grew from $22.7m to $37.7m (+66%), an average of +14% a year. The sharpest change came in the year to December 2022, when income rose by 379%. Over the whole period it spent 50% of the income it received.

Among 45,478 United States charities whose main cause is arts, culture, heritage and science and that reported income, Alzheimers Drug Discovery Foundation sits at the 99th percentile: it is one of the largest 1% in its cause. Against every charity in United States with reported income it ranks in the 98th percentile, and in the 97th percentile within NY. Charities of a similar size with the same main cause include New York Structural Biology Center Inc ($37.7m), Open Technology Fund ($38.0m) and Anita Borg Institute for Women and Technology ($37.7m).

On its Form 990 for the period ending December 2023, revenue came from contributions and grants 81% and program service revenue 11% of the total. Compensation of current officers, directors and key employees was $1.7m (2.8% of expenses). Other salaries and wages came to $4.8m. At year end it held assets of $324.2m against liabilities of $64.2m, net assets of $260.0m. It reported 47 employees.